Patents Assigned to MGI Pharma Biologics, Inc.
-
Publication number: 20100233087Abstract: The present invention provides nucleic acids containing transcriptional units that encode CYP1B1 polypeptides or portions thereof, wherein the transcriptional units lack sequences found in the untranslated region (UTR) of naturally occurring forms of the CYP1B1 transcript. The nucleic acids of the invention lack translational repressor elements and thus provide for a system of enhanced translation of the CYP1B1 polypeptide or portions thereof. Also disclosed are methods of administering nucleic acids to a mammal and use in the treatment of proliferative disorders or cancer.Type: ApplicationFiled: April 30, 2007Publication date: September 16, 2010Applicant: MGI PHARMA BIOLOGICS, INC.Inventors: Nazneen Aziz, Mary Lynne Hedley, Robert G. Urban, Andrew J. Tomlinson, Geoffrey Cole
-
Patent number: 7408029Abstract: The invention provides methods for identifying peptide epitopes that activate CD4+ T cells involved in the pathogenesis of diseases, e.g., autoimmune diseases, susceptibility to which is determined by expression of particular class II MHC genes. The invention includes peptides derived from the IA-2 polypeptide by such a method, altered peptide ligands, and methods of therapy involving the use of altered peptide ligands.Type: GrantFiled: February 2, 2007Date of Patent: August 5, 2008Assignees: MGI PHARMA Biologics, Inc., King's College LondonInventors: Mark Peakman, Roman M. Chicz
-
Patent number: 7408031Abstract: The invention provides methods for identifying peptide epitopes that activate CD4+ T cells involved in the pathogenesis of diseases, e.g., autoimmune diseases, susceptibility to which is determined by expression of particular class II MHC genes. The invention includes peptides derived from the IA-2 polypeptide by such a method, altered peptide ligands, and methods of therapy involving the use of altered peptide ligands.Type: GrantFiled: February 2, 2007Date of Patent: August 5, 2008Assignees: MGI PHARMA Biologics, Inc., King's College LondonInventors: Mark Peakman, Roman M. Chicz
-
Patent number: 7241742Abstract: The present invention provides nucleic acids containing transcriptional units that encode CYP1B1 polypeptides or portions thereof, wherein the transcriptional units lack sequences found in the untranslated region (UTR) of naturally occurring forms of the CYP1B1 transcript. The nucleic acids of the invention lack translational repressor elements and thus provide for a system of enhanced translation of the CYP1B1 polypeptide or portions thereof. Also disclosed are methods of administering nucleic acids to a mammal and use in the treatment of proliferative disorders or cancer.Type: GrantFiled: October 31, 2001Date of Patent: July 10, 2007Assignee: MGI PHARMA Biologics, Inc.Inventors: Nazneen Aziz, Mary Lynne Hedley, Robert G. Urban, Andrew J. Tomlinson, Geoffrey Cole
-
Publication number: 20070142622Abstract: The invention provides methods for identifying peptide epitopes that activate CD4+ T cells involved in the pathogenesis of diseases, e.g., autoimmune diseases, susceptibility to which is determined by expression of particular class II MHC genes. The invention includes peptides derived from the IA-2 polypeptide by such a method, altered peptide ligands, and methods of therapy involving the use of altered peptide ligands.Type: ApplicationFiled: February 2, 2007Publication date: June 21, 2007Applicants: MGI PHARMA Biologics, Inc., King's College LondonInventors: Mark Peakman, Roman Chicz
-
Publication number: 20070135618Abstract: The invention provides methods for identifying peptide epitopes that activate CD4+ T cells involved in the pathogenesis of diseases, e.g., autoimmune diseases, susceptibility to which is determined by expression of particular class II MHC genes. The invention includes peptides derived from the IA-2 polypeptide by such a method, altered peptide ligands, and methods of therapy involving the use of altered peptide ligands.Type: ApplicationFiled: February 2, 2007Publication date: June 14, 2007Applicants: MGI PHARMA Biologics, Inc., King's College LondonInventors: Mark Peakman, Roman Chicz
-
Patent number: 7173108Abstract: The invention provides methods for identifying peptide epitopes that activate CD4+ T cells involved in the pathogenesis of diseases, e.g., autoimmune diseases, susceptibility to which is determined by expression of particular class II MHC genes. The invention includes peptides derived from the IA-2 polypeptide by such a method, altered peptide ligands, and methods of therapy involving the use of altered peptide ligands.Type: GrantFiled: March 3, 2003Date of Patent: February 6, 2007Assignees: MGI Pharma Biologics, Inc., King's College LondonInventors: Mark Peakman, Roman M. Chicz
-
Patent number: 7169603Abstract: The invention provides polypeptides containing ?-MSH that can be used to treat diseases characterized by inflammation and/or autoimmunity. Also included in the invention are ?-MSH analogs and nucleic acids encoding polypeptides containing ?-MSH and ?-MSH analogs optionally linked to heterologous sequences. Also included in the invention are methods of delivering ?-MSH containing peptides, ?-MSH analogs, an DNA encoding ?-MSH and ?-MSH analogs.Type: GrantFiled: July 16, 2001Date of Patent: January 30, 2007Assignee: MGI Pharma Biologics, Inc.Inventors: Mary Lynne Hedley, Robert G. Urban, Nazneen Aziz, Hongmin Chen, Bijan Etemad-Moghadam, Peng Yin
-
Patent number: 7097843Abstract: The invention provides immunogenic peptides from the HPV type 16 E7 protein that comprise overlapping class I restricted T cell epitopes. Also disclosed are methods of administering DNA molecules encoding these peptides to a host mammal.Type: GrantFiled: June 24, 2003Date of Patent: August 29, 2006Assignee: MGI Pharma Biologics, Inc.Inventors: Robert G. Urban, Roman M. Chicz, Edward J. Collins, Mary Lynne Hedley